Page results
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
This page is for cancer patients receiving immunotherapy treatment.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
A national study with initial results shows steroid dexamethasone may substantially reduce mortality in severely ill Covid-19 patients.
-
You now need a registered site administrator to access EpicCare Link UCLH for your practice or service. If your site doesn’t have a registered administrator, you may lose access to EpicCare Link UCLH.
-
The Neurorehabilitation Unit (NRU) at The National Hospital for Neurology and Neurosurgery (NHNN) has been refurbished with funding from The National Brain Appeal to provide new facilities and additional space, transforming it into a more therapeutic environment.
-
Bladder cancer is where a growth of abnormal tissue, known as a tumour, develops in the bladder lining. In some cases, the tumour spreads into the surrounding areas.
-
UCLH research manager Sarah Taylor has won a national leadership award for her work to develop and train research staff.
-
A new research study at UCLH and UCL will investigate how a rare type of blood cancer develops and what types of treatment may be effective for patients.
